Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro

Biochemical Pharmacology

Volumn 93, Issue 1, 2015, Pages 59-71

  Wu, Chuanlong ^a   Wang, Wengang ^a   Tian, Bo ^a   Liu, Xuqiang ^a   Qu, Xinhua ^a   Zhai, Zanjing ^a   Li, Haowei ^a   Liu, Fengxiang ^a   Fan, Qiming ^a   Tang, Tingting ^a   Qin, An ^a   Zhu, Zhenan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

MAPK signaling; NF B signaling; Osteoclast formation; Osteoclastic bone resorption; Periprosthetic osteolysis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADENOSINE TRIPHOSPHATASE; CALCITONIN RECEPTOR; CATHEPSIN K; F ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MYRICETIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE 1; SYNAPTOPHYSIN; TITANIUM; TRANSCRIPTION FACTOR NFAT; FLAVONOID; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CALVARIA; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME INHIBITION; IC50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; MALE; OSTEOCLAST; PARTICLE SIZE; PATHOLOGY; PREVENTION AND CONTROL; RANDOMIZATION; TOXICITY;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; MALE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOLYSIS; PARTICLE SIZE; RANDOM ALLOCATION; RANK LIGAND; TITANIUM;

EID: 84919774972     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.10.019     Document Type: Article

References (60)

1. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008;20:86-100.
2. Long M, Rack HJ. Titanium alloys in total joint replacement-a materials science perspective. Biomaterials 1998;19:1621-39.
3. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990;87:7260-4.
4. Takahashi N, Udagawa N, Tanaka S, Suda T. Generating murine osteoclasts from bone marrow. Methods Mol Med 2003;80:129-44.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
6. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 2005;57: 389-95.
7. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res Off Publ Orthop Res Soc 2003;21:202-12.
8. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983;306:378-80.
9. Pioletti DP, Kottelat A. The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. Biomaterials 2004;25:5803-8.
10. Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, et al. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 2006;27:5212-9.
11. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, et al. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am Vol 1993;75:863-79.
12. Novack DV. Role of NF-kappaB in the skeleton. Cell Res 2011;21:169-82.
13. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
14. Yanez J, Vicente V, Alcaraz M, Castillo J, Benavente-Garcia O, Canteras M, et al. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer 2004;49:191-9.
15. Blonska M, Czuba ZP, Krol W. Effect of flavone derivatives on interleukin-1beta (IL-1beta) mRNA expression and IL-1beta protein synthesis in stimulated RAW 264.7 macrophages. Scand J Immunol 2003;57:162-6.
16. Wang J, Mazza G. Inhibitory effects of anthocyanins and other phenolic compounds on nitric oxide production in LPS/IFN-gamma-activated RAW 264.7 macrophages. J Agric Food Chem 2002;50:850-7.
17. Kuo PL. Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci 2005;77:2964-76.
18. Hsu YL, Chang JK, Tsai CH, Chien TT, Kuo PL. Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway. Biochem Pharmacol 2007;73: 504-14.
19. Yamaguchi M, Hamamoto R, Uchiyama S, Ishiyama K. Effects of flavonoid on calcium content in femoral tissue culture and parathyroid hormone-stimulated osteoclastogenesis in bone marrow culture in vitro. Mol Cell Biochem 2007;303:83-8.
20. Ko SY. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells. Arch Oral Biol 2012;57:1623-32.
21. Jin S, Park JY, Hong JM, Kim TH, Shin HI, Park EK, et al. Inhibitory effect of (-)- epigallocatechin gallate on titanium particle-induced TNF-alpha release and in vivo osteolysis. Exp Mol Med 2011;43:411-8.
22. Liu F, Zhu Z, Mao Y, Liu M, Tang T, Qiu S. Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide. Biomaterials 2009;30:1756-62.
23. Qin A, Cheng TS, Lin Z, Cao L, Chim SM, Pavlos NJ, et al. Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PloS One 2012;7:e34132.
24. Wedemeyer C, Xu J, Neuerburg C, Landgraeber S, Malyar NM, von Knoch F, et al. Particle-induced osteolysis in three-dimensional micro-computed tomography. Calcified Tissue Int 2007;81:394-402.
25. Toro EJ, Zuo J, Ostrov DA, Catalfamo D, Bradaschia-Correa V, Arana-Chavez V, et al. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem 2012;287:17894-904.
26. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J. 12-O-tetradecanoyl-phorbol- 13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-B activation.pdf〉. J Bone Miner Res 2003;18.
27. Helfrich MH. Osteoclast diseases and dental abnormalities. Arch Oral Biol 2005;50:115-22.
28. Abu-Amer Y, Darwech I, Clohisy JC. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Therapy 2007;9(Suppl. 1):S6.
29. Marx RE. The deception and fallacies of sponsored randomized prospective double-blinded clinical trials: the bisphosphonate research example. Int J Oral Maxillofacial Implants 2014;29:e37-44.
30. Maeda SS, Lazaretti-Castro M. An overview on the treatment of postmenopausal osteoporosis. Arquivos Brasileiros de Endocrinologia e Metabologia 2014;58:162-71.
31. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once- Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97:3097-106.
32. Hiligsmann M, Boonen A, Dirksen CD, Ben Sedrine W, Reginster JY. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res 2013;13:19-28.
33. Bi Y, Seabold JM, Kaar SG, Ragab AA, Goldberg VM, Anderson JM, et al. Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res Off J Am Soc Bone Miner Res 2001;16:2082-91.
34. Wilson SR, Peters C, Saftig P, Bromme D, Cathepsin. K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biolog Chem 2009;284:2584-92.
35. Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S, et al. Bone resorption in syndromes of the Ras/MAPK pathway. Clin Genet 2011;80: 566-73.
36. Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biolog Chem 2007;282:33435-43.
37. Takaesu G, Ninomiya-Tsuji J, Kishida S, Li X, Stark GR, Matsumoto K. Interleukin- 1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol 2001;21: 2475-84.
38. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl):S81-96.
39. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Develop 1997;11:3482-96.
40. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nature Med 1997;3:1285-9.
41. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-9.
42. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c- Fos and NFATc1. J Biol Chem 2007;282:18245-53.
43. Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 2007;282:15921-29.
44. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279:45969-79.
45. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006;351:99-105.
46. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R. Absence of fenfluramine- induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci Off J Soc Neurosci 1998;18:5537-44.
47. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Develop Cell 2002;3:889-901.
48. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Van De Motter RR. The role of osteoclast differentiation in aseptic loosening. J Orthop Res Off Publ Orthop Res Soc 2002;20:1-8.
49. Holt G, Murnaghan C, Reilly J, Meek RM. The biology of aseptic osteolysis. Clin Orthop Relat Res 2007;460:240-52.
50. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999;154:203-10.
51. Rakshit DS, Ly K, Sengupta TK, Nestor BJ, Sculco TP, Ivashkiv LB, et al. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. J Bone Joint Surg Am Vol 2006;88:788-99.
52. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, et al. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am Vol 1999;81:603-15.
53. Wang W, Ferguson DJ, Quinn JM, Simpson AH, Athanasou NA. Biomaterial particle phagocytosis by bone-resorbing osteoclasts. J Bone Joint Surg Brit Vol 1997;79:849-56.
54. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 2007;454:251-61.
55. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol 2008;61:577-87.
56. Hirakawa K, Bauer TW, Stulberg BN, Wilde AH. Comparison and quantitation of wear debris of failed total hip and total knee arthroplasty. J Biomed Mater Res 1996;31:257-63.
57. Baumann B, Seufert J, Jakob F, Noth U, Rolf O, Eulert J, et al. Activation of NF-kappaB signalling and TNFalpha-expression in THP-1 macrophages by TiAlVand polyethylene-wear particles. J Orthop Res Off Publ Orthop Res Soc 2005;23:1241-8.
58. von Knoch M, Jewison DE, Sibonga JD, Sprecher C, Morrey BF, Loer F, et al. The effectiveness of polyethylene versus titanium particles in inducing osteolysis in vivo. J Orthop Res Off Publ Orthop Res Soc 2004;22:237-43.
59. Masui T, Sakano S, Hasegawa Y, Warashina H, Ishiguro N. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 2005;26: 1695-702.
60. Baumann B, Rader CP, Seufert J, Noth U, Rolf O, Eulert J, et al. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthop Scand 2004;75:295-302.